Search results
Showing 136 to 150 of 1490 results for patients and public
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development Reference number: GID-TA11096 Expected publication date: TBC
In development Reference number: GID-TA10979 Expected publication date: TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: 04 June 2026
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.
View quality statements for QS50Show all sections
Sections for QS50
- Quality statements
- Quality statement 1: Participation in meaningful activity
- Quality statement 2: Personal identity
- Quality statement 3: Recognition of mental health conditions
- Quality statement 4: Recognition of sensory impairment
- Quality statement 5: Recognition of physical problems
- Quality statement 6: Access to healthcare services
- Update information
In development Reference number: GID-TA11649 Expected publication date: 14 October 2026
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]
In development Reference number: GID-TA11818 Expected publication date: 14 April 2027
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)
In development Reference number: GID-HTE10085 Expected publication date: 02 December 2026
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
In development Reference number: GID-TA11023 Expected publication date: TBC
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.